RxDoctor Payments Data

Susan Longar, MD

Ophthalmology · Daly City, CANPI 1578506960

Payments from drug & device makers

$2,873in general payments, 2019–2025

Across 136 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$378
  • Bausch & Lomb Americas Inc.$346
  • Alcon$290
  • Mallinckrodt Hospital Products Inc.$258
  • Oyster Point Pharma, Inc.$225
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$198
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,62691%
  • Education$2479%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,873 in reported general payments places this provider in the 65th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$395,529
Medicare patients
1,017
Services billed
4,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast78$74,548
LumiganBimatoprost113$58,699
RocklatanNetarsudil Mesylat/Latanoprost43$22,168
RestasisCyclosporine13$19,893
Latanoprost1,115$17,875
RhopressaNetarsudil Mesylate30$15,743
TyrvayaVarenicline Tartrate14$14,338
Prednisolone Acetate248$11,813
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol37$11,303
Travoprost32$8,272
Cyclosporine13$7,196
MoxifloxacinMoxifloxacin Hcl276$6,957
Brinzolamide24$6,357
Brimonidine Tartrate47$5,136
SimbrinzaBrinzolamide/Brimonidine Tart12$4,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$378$78,592126 claims
Bausch & Lomb Americas Inc.Xiidra$346$74,54878 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$74$37,91173 claims
Oyster Point Pharma, Inc.Tyrvaya$225$14,33814 claims
AlconSimbrinza$290$4,57612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Daly City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →